Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, discuss data updates from the TROPION-PanTumor01 study that impact the use of antibody-drug conjugates as a therapy option for patients with second-line metastatic non-small cell lung cancer.
EP. 1: Second-Line Metastatic NSCLC: Treatment Landscape and Challenges
Rebecca Suk Heist, MD, MPH, discusses the treatment landscape and challenges when treating patients with second-line metastatic non-small cell lung cancer.
EP. 2: Defining Trop-2 and Antibody-Drug Conjugates in NSCLC
Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, define Trop-2 in relation to treatments for non-small cell lung cancer and discuss what antibody-drug conjugates are being developed to target it.
EP. 3: TROPION-PanTumor01 Study Design and Primary Data Analysis
Drs Heist and Peters examine data from the lung cohort of TROPION-PanTumor01 study that focused on dopotomab deruxtecan (Dato-DXd) as an antibody-drug conjugate therapy option.
EP. 4: Additional Studies with Antibody-Drug Conjugates in NSCLC
Two experts discuss additional studies with antibody-drug conjugates targeting non-small cell lung cancer and the impact of their data on therapeutic options for the disease.
EP. 5: Future Outlook
Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, reflect on treatments being developed in the non-small cell lung cancer space that they are excited for and provide some key takeaways and advice for colleagues.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512